Neurocrine Biosciences 주식 (NASDAQ: NBIX)

에 대한 최신 뉴스 Neurocrine Biosciences (NASDAQ:NBIX) 주식

Neurocrine Biosciences

Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.

Large Cap

News

Movers

INTC

MRNA

NBIX

Citigourp Global Markets 2% Protected Notes Linked To The Djia

SMCI

SNAP

이들 10개 대형주는 8월에 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 1. 슈퍼 마이크로 컴퓨터(NASDAQ:SMCI)의 주식은 8월에 34.89% 하락했다. 이 회사는 10-K 제출을 연기했다.

인텔, 모더나 그리고 달러 제너럴은 8월 최악의 성과를 보인 10개 대형주 중 일부

Trading Ideas

COIN

DLTR

MSTR

OKTA

PSTG

이들 10개 대형주는 지난주 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 1. 달러 제너럴(NYSE:DG)의 주식은 회사가 2분기 실적과 매출이 예상보다 저조하게 나타났으며 2024년 가이던스를 하향 조정했다고 발표한 후 32.42% 하락했다. 많은 애널리스트들이 주가 목표를 하향 조정했다.

달러 제너럴 및 테무의 모회사 PDD는 지난주 최악의 성과를 보인 10개 대형주 중 일부 (8월 25일-8월 31일)

Neurocrine Biosciences, Inc. - Common Stock

Neurocrine Biosciences Inc

NEUROCRINE BIOSCIENCES ORD

Biotech

General

Neurocrine Biosciences Unveils KINECT-HD Data Demonstrating Consistent Efficacy Of INGREZZA In Huntington's Disease Chorea Across 19 Subgroups, Showing Positive Impact On Emotional Health

Neurocrine Biosciences Reveals New INGREZZA Data At Psych Congress 2024, Showing 60% Remission Rate For Tardive Dyskinesia After 48 Weeks In Long-Term Study

HC Wainwright &amp; Co. analyst Andrew Fein reiterates Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) with a Buy and maintains $190 price target.

Price Target

Reiteration

Analyst Ratings

HC Wainwright & Co. Reiterates Buy on Neurocrine Biosciences, Maintains $190 Price Target

Needham analyst Ami Fadia reiterates Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) with a Hold.

Needham Reiterates Hold on Neurocrine Biosciences

WIIM

Neurocrine Biosciences shares are trading higher after the company reported better-than-expected Q3 financial results and raised annual valbenazine revenue outlook. It also authorized $300 million stock buyback.

Guidance

Neurocrine Biosciences Raises FY24 Net Product (valbenazine) Revenue Outlook To $2.30B-$2.32B

Announced the Company's Board of Directors has authorized a $300 million share repurchase plan. The Company subsequently intends to enter into a $300 million accelerated share repurchase transaction in the coming days, subject to market conditions, which will constitute the entirety of the authorized share repurchase plan.

Buybacks

Neurocrine Biosciences Board Authorizes $300M Stock Buyback

Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) reported quarterly earnings of $1.81 per share which beat the analyst consensus estimate of $1.51 by 19.87 percent. This is a 17.53 percent increase over earnings of $1.54 per share from the same period last year. The company reported quarterly sales of $622.100 million which beat the analyst consensus estimate of $600.628 million by 3.57 percent. This is a 24.72 percent increase over sales of $498.800 million the same period last year.

Earnings

Earnings Beats

Neurocrine Biosciences Q3 2024 Adj. EPS $1.81 Beats $1.51 Estimate, Sales $622.100M Beat $600.628M Estimate

Providing a diverse range of perspectives from bullish to bearish, 20 analysts have published ratings on Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) in the last three months.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">9</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $161.9, with a high estimate of $219.00 and a low estimate of $114.00. This current average reflects an increase of 1.99% from the previous average price target of $158.74. 
<img src="https://www.benzinga.com/files/images/story/2024/1730203251_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Neurocrine Biosciences. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Evan Seigerman</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$114.00</td>
<td>$128.00</td>
</tr>
<tr>
<td>Danielle Brill</td>
<td>Raymond James</td>
<td>Announces</td>
<td>Outperform</td>
<td>$155.00</td>
<td>-</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$133.00</td>
<td>$133.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$133.00</td>
<td>$136.00</td>
</tr>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$155.00</td>
<td>$155.00</td>
</tr>
<tr>
<td>Carter Gould</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$160.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$155.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Evan Seigerman</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$128.00</td>
<td>$142.00</td>
</tr>
<tr>
<td>David Amsellem</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$159.00</td>
<td>$131.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$136.00</td>
<td>$143.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$190.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Akash Tewari</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$189.00</td>
<td>$177.00</td>
</tr>
<tr>
<td>Anupam Rama</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$181.00</td>
<td>$173.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$190.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$143.00</td>
<td>$136.00</td>
</tr>
<tr>
<td>Yatin Suneja</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$180.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>David Hoang</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$158.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Jay Olson</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$219.00</td>
<td>$216.00</td>
</tr>
<tr>
<td>Carter Gould</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$180.00</td>
<td>$169.00</td>
</tr>
<tr>
<td>Brian Skorney</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$180.00</td>
<td>$157.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Neurocrine Biosciences. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Neurocrine Biosciences compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Neurocrine Biosciences's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Neurocrine Biosciences's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/NBIX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Neurocrine Biosciences analyst ratings.</a>
<h2>Get to Know Neurocrine Biosciences Better</h2>
Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.
<h3>Understanding the Numbers: Neurocrine Biosciences's Finances</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Neurocrine Biosciences's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 30.37%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Neurocrine Biosciences's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 11.01%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Neurocrine Biosciences's ROE stands out, surpassing industry averages. With an impressive ROE of 2.66%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Neurocrine Biosciences's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.92% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Neurocrine Biosciences's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.1.
<h2>Analyst Ratings: What Are They?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

In-Depth Examination Of 20 Analyst Recommendations For Neurocrine Biosciences

BMO Capital analyst Evan Seigerman maintains Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) with a Market Perform and lowers the price target from $128 to $114.

BMO Capital Maintains Market Perform on Neurocrine Biosciences, Lowers Price Target to $114

Raymond James analyst Danielle Brill reinstates Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) with a Outperform and announces $155 price target.

Initiation

Raymond James Reinstates Outperform on Neurocrine Biosciences, Announces $155 Price Target

RBC Capital analyst Brian Abrahams reiterates Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) with a Sector Perform and maintains $133 price target.

RBC Capital Reiterates Sector Perform on Neurocrine Biosciences, Maintains $133 Price Target

During the last three months, 20 analysts shared their evaluations of Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>), revealing diverse outlooks from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">11</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $166.7, along with a high estimate of $219.00 and a low estimate of $128.00. This upward trend is evident, with the current average reflecting a 2.93% increase from the previous average price target of $161.95.
<img src="https://www.benzinga.com/files/images/story/2024/1728057676_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
A comprehensive examination of how financial experts perceive Neurocrine Biosciences is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$133.00</td>
<td>$136.00</td>
</tr>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$155.00</td>
<td>$155.00</td>
</tr>
<tr>
<td>Carter Gould</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$160.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$155.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Evan Seigerman</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$128.00</td>
<td>$142.00</td>
</tr>
<tr>
<td>David Amsellem</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$159.00</td>
<td>$131.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$136.00</td>
<td>$143.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$190.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Akash Tewari</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$189.00</td>
<td>$177.00</td>
</tr>
<tr>
<td>Anupam Rama</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$181.00</td>
<td>$173.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$190.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$143.00</td>
<td>$136.00</td>
</tr>
<tr>
<td>Yatin Suneja</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$180.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>David Hoang</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$158.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Jay Olson</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$219.00</td>
<td>$216.00</td>
</tr>
<tr>
<td>Carter Gould</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$180.00</td>
<td>$169.00</td>
</tr>
<tr>
<td>Brian Skorney</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$180.00</td>
<td>$157.00</td>
</tr>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$155.00</td>
<td>$155.00</td>
</tr>
<tr>
<td>Jeffrey Hung</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$170.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Anupam Rama</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$173.00</td>
<td>$169.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Neurocrine Biosciences. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Neurocrine Biosciences compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Neurocrine Biosciences's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Neurocrine Biosciences's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/NBIX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Neurocrine Biosciences analyst ratings.</a>
<h2>Discovering Neurocrine Biosciences: A Closer Look</h2>
Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.
<h3>Neurocrine Biosciences's Financial Performance</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Neurocrine Biosciences's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 30.37%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Neurocrine Biosciences's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 11.01%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Neurocrine Biosciences's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.66% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Neurocrine Biosciences's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.92%, the company showcases efficient use of assets and strong financial health.
Debt Management: Neurocrine Biosciences's debt-to-equity ratio is below the industry average. With a ratio of 0.1, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Critical Insights From Neurocrine Biosciences Analyst Ratings: What You Need To Know

RBC Capital analyst Brian Abrahams maintains Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) with a Sector Perform and lowers the price target from $136 to $133.

RBC Capital Maintains Sector Perform on Neurocrine Biosciences, Lowers Price Target to $133

Neurocrine Biosciences Highlights Presentation Of Interim Data Showing Robust And Sustained Improvements In Chorea Associated With Huntington's Disease Through Week 104 Irrespective Of Antipsychotic Use

Cantor Fitzgerald analyst Charles Duncan reiterates Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) with a Overweight and maintains $155 price target.

Cantor Fitzgerald Reiterates Overweight on Neurocrine Biosciences, Maintains $155 Price Target

Neurocrine Biosciences Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) ERUDITE phase two clinical study of investigational compound luvadaxistat (NBI-1065844) failed to meet its primary endpoint as a potential treatment to improve cognitive <a href="https://www.benzinga.com/pressreleases/24/09/n40842532/neurocrine-biosciences-provides-update-on-erudite-phase-2-data-for-luvadaxistat-in-adults-with-cog" target="_blank" rel="noreferrer noopener">impairment in schizophrenia patients</a>.
It failed to replicate the cognitive endpoint data seen in the earlier INTERACT study due in part to the large variability seen in the cognitive measures across the population studied and a potential imbalance in the baseline characteristics of subjects enrolled across the treatment arms.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40632561/neurocrine-biosciences-lower-dose-data-puts-its-schizophrenia-candidate-in-the-game" rel="noreferrer noopener">Neurocrine Biosciences&#8217; Lower Dose Data Puts Its Schizophrenia Candidate In The Game, Analyst Upgrades Stock</a>
In the INTERACT study, 50 mg luvadaxistat resulted in a statistically significant improvement in the measure of cognition on the Brief Assessment of Cognition in Schizophrenia (BACS) and cognitive performance on the Schizophrenia Cognition Rating Scale (SCoRS).
The INTERACT study was the first to demonstrate statistical significance for both cognitive measures and function within a single study.
The company stated it was disappointed that luvadaxistat did not meet the primary endpoint in this study and it understood the challenges and hurdles that exist in identifying potential medicines for the treatment of cognitive impairment in schizophrenia.
Neurocrine Biosciences will halt further development of luvadaxistat and instead will focus on the advancement into phase three development of NBI-1117568 for schizophrenia and NBI-1065845 for major depressive disorder.
In August, Neurocrine Biosciences shared topline data for its phase one study of NBI-1117568 (NBI-‘568) in&nbsp;<a href="https://www.benzinga.com/pressreleases/24/08/n40596900/neurocrine-biosciences-reports-positive-phase-2-data-for-nbi-1117568-in-adults-with-schizophrenia" target="_blank" rel="noreferrer noopener">adults with schizophrenia</a>.
The new data showed that the once-daily 20 mg dose of NBI-‘568 induced an average 18.2-point reduction from baseline in the Positive and Negative Syndrome Scale (PANSS) after six weeks, compared to 10.8 <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40604853/as-regulators-gear-up-to-decide-on-bristol-myers-schizophrenia-treatment-neurocrine-biosciences-d" rel="noreferrer noopener">points in the placebo group</a>.
William Blair noted further value can be unlocked through the expanding Ingrezza business, the anticipated near-term launch of crinecerfont for treating congenital adrenal hyperplasia (CAH), with PDUFA dates set for Dec. 29 and 30, 2024, and the company's mid-stage portfolio.
The analyst reiterated the Outperform <a href="https://www.benzinga.com/quote/NBIX/analyst-ratings" target="_blank" rel="noreferrer noopener">rating on Neurocrine</a>.
NBIX Price Action: Neurocrine Biosciences stock is up 0.82% at $122.27 at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/m-a/24/09/40853165/sony-eyes-500m-deal-for-pink-floyds-iconic-music-catalog-report" target="_blank" rel="noreferrer noopener">Sony Eyes $500M Deal for Pink Floyd&#8217;s Iconic Music Catalog: Report</a>.</li>
</ul>
Photo: Romix Image via Shutterstock

Analyst Color

Health Care

Neurocrine Shifts Focus To New Schizophrenia Treatment After Luvadaxistat Trial Misses Endpoint

<ul>
<li>Second Phase 2 Study for Luvadaxistat Fails to Meet Primary Endpoint as Potential Treatment for Cognitive Impairment Associated with Schizophrenia</li>
<li>Results Confounded by Variability in Cognition Measures Across Population Studied and Potential Imbalance in Baseline Characteristics of Enrolled Subjects
<ul>
<li>Neurocrine Biosciences to Focus Resources on Phase 3 Clinical Development of NBI-1117568 for Schizophrenia and NBI-1065845 for Major Depressive Disorder</li>
</ul>
</li>
</ul>

Neurocrine Biosciences Provides Update on ERUDITE™Phase 2 Data For Luvadaxistat

Neurocrine Biosciences (NBIX) has disclosed a new risk, in the Share Price & Shareholder Rights category. Neurocrine Biosciences faces potential un...

Neurocrine Biosciences' $300M Share Buyback Plan: Potential Risks and Market Volatility Concerns

Bank of America Securities analyst Tazeen Ahmad has reiterated their bullish stance on NBIX stock, giving a Buy rating today. Tazeen Ahmad has give...

Strong Performance and Promising Pipeline Drive Buy Rating for Neurocrine Biosciences

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Neurocrine (NBIX – Research Report) and Evolus (EOLS...

Wall Street Analysts Are Bullish on Top Healthcare Picks

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Vir Biotechnology (VIR – Research Report), Intra-C...

Analysts Offer Insights on Healthcare Companies: Vir Biotechnology (VIR), Intra-Cellular Therapies (ITCI) and Neurocrine (NBIX)

Neurocrine (NBIX) Biosciences presented data from more than 300 patients diagnosed with tardive dyskinesia and treated with INGREZZA, or valbenazin...

Neurocrine presents data from Ingrezza studies on tardive dyskines patients

Mid-cap stocks with 'significant scope' to upside – WF

In a report released yesterday, Paul Matteis from Stifel Nicolaus maintained a Buy rating on Neurocrine (NBIX – Research Report), with a price targ...

Stifel Nicolaus Remains a Buy on Neurocrine (NBIX)

Canaccord Genuity analyst Sumant Kulkarni maintained a Buy rating on Neurocrine (NBIX – Research Report) yesterday and set a price target of $167.0...

Strong Sales and Strategic Moves Bolster Neurocrine's Buy Rating

Needham analyst Ami Fadia has maintained their neutral stance on NBIX stock, giving a Hold rating on October 31. Ami Fadia's rating is based on sev...

Neurocrine Biosciences: Balancing Strategic Priorities with Regulatory Challenges – Analyst Maintains Hold Rating

Why Neurocrine Biosciences Stock Is Very Attractive At Current Levels

BURL

CACI

CRWD

CTRA

EOLS

FERG

GWRE

HUBS

ITCI

MDYG

MPWR

MUSA

PFGC

ROST

SPOT

TEVA

TEVJF

TRGP

UTHR

Press Releases

Neurocrine Biosciences to Participate at the 2024 Cantor Global Healthcare Conference

Neurocrine Biosciences Provides Update on ERUDITE™ Phase 2 Data for Luvadaxistat in Adults with Cognitive Impairment Associated with Schizophrenia

Neurocrine Biosciences to Participate at the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Virtual Summit

Neurocrine Biosciences Presents Interim Data Demonstrating Robust and Sustained Improvements in Chorea Associated With Huntington's Disease Through Week 104 Irrespective of Antipsychotic Use

Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2024 Financial Results

Neurocrine Biosciences Reports Third Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance

Neurocrine Biosciences Presents New Data on INGREZZA® (valbenazine) Capsules at Psych Congress 2024: Majority of Long-Term Study Participants Achieved Remission of Tardive Dyskinesia

Neurocrine Biosciences Presents Breadth of Data Demonstrating Holistic Improvements Over Time in Patients With Tardive Dyskinesia Following Treatment With INGREZZA® (valbenazine) Capsules

Neurocrine Biosciences to Participate at Investor Conferences in November

Neurocrine Biosciences Presents New KINECT®-HD Data Showing Consistent Efficacy Across 19 Subgroups and Improvements in Aspects of Emotional Health With INGREZZA® (valbenazine) Capsules

AbbVie

Alnylam Pharmaceuticals, Inc. - Common Stock

Alnylam Pharmaceuticals

Amgen

argenx

BeiGene, Ltd. - American Depositary Shares

BeiGene

Biogen

BioMarin Pharmaceutical Inc. - Common Stock

Biomarin Pharmaceutical

BioNTech

Exact Sciences Corporation - Common Stock

Exact Sciences

Exelixis

Gilead Sciences

Genmab

Incyte

Insmed

Madrigal Pharmaceuticals, Inc. - Common Stock

Madrigal Pharmaceuticals

Moderna

Natera

Vaxcyte

Regeneron Pharmaceuticals, Inc. - Common Stock

Regeneron Pharmaceuticals

Roivant Sciences

Revolution Medicines, Inc. - Common Stock

Revolution Medicines

Summit Therapeutics

Sarepta Therapeutics, Inc. - Common Stock

Sarepta Therapeutics

United Therapeutics Corporation - Common Stock

United Therapeutics

Vertex Pharmaceuticals Incorporated - Common Stock

Vertex Pharmaceuticals

HC Wainwright & Co.

BMO Capital

Raymond James

RBC Capital

Cantor Fitzgerald

이들 10개 대형주는 8월에 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
1. 슈퍼 마이크로 컴퓨터(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>)의 주식은 8월에 34.89% 하락했다. 이 회사는 <a href="https://www.benzinga.com//node/40602417" target="_blank" rel="noreferrer noopener">10-K 제출을 연기</a>했다.
2. 달러 제너럴(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DG#NYSE">DG</a>)의 주식은 30.95% 하락했다. 이 회사는 예상보다 저조한 2분기 실적을 발표했으며, 많은 애널리스트들이 <a href="https://www.benzinga.com//node/40656935" target="_blank" rel="noreferrer noopener">주가 목표를 하향 조정</a>했다.
3. 스냅(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNAP#NYSE">SNAP</a>)의 주식은 27.09% 급락했다. 이 회사는 2분기에 매출이 예상보다 저조하다고 발표하고, <a href="https://www.benzinga.com//node/40132594" target="_blank" rel="noreferrer noopener">애널리스트들이 주가 목표를 대폭 하향 조정</a>했다.
4. 테무의 모회사 PDD 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDD#NASDAQ">PDD</a>)의 주식은 24.81% 하락했다. 이 회사가 분기 실적을 발표하고 CEO가 <a href="https://www.benzinga.com/news/earnings/24/08/40548945/temu-parent-pdd-posts-86-q2-topline-growth-stock-drops-after-ceo-flags-upcoming-challenges?_gl=1%2A2quf99%2A_gcl_au%2ANzQ5NDg4Nzg3LjE3MjI5NDg1NTA.%2A_ga%2AMTUwODg0NTczNy4xNzE1MTcxNjk4%2A_ga_V7ZK73W7N0%2AMTcyNTYyNjczNi4xMzIuMS4xNzI1NjQ0MzU2LjAuMC4w" target="_blank" rel="noreferrer noopener">올해 남은 기간에 대한 도전 과제를 강조</a>했다.
5. 인텔(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>)의 주식은 24.13% 하락했다. 이 회사는 저조한 분기 실적과 <a href="https://www.benzinga.com//node/40115276" target="_blank" rel="noreferrer noopener">15% 인력 감축 계획</a>을 발표했다.
6. 텐센트 뮤직 엔터테인먼트 그룹(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TME#NYSE">TME</a>)의 주식은 21.44% 하락했다. 이 회사는 2분기 매출이 예상보다 저조하다고 발표하고, <a href="https://www.benzinga.com//node/40373910" target="_blank" rel="noreferrer noopener">애널리스트들이 주가 목표를 하향 조정</a>했다.
6. 골드 필드(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GFI#NYSE">GFI</a>)의 주식은 18.99% 하락했다. 이 회사가 오시스코 마이닝(<a href="https://www.benzinga.com//node/40309407" target="_blank" rel="noreferrer noopener">Osisko Mining)</a>을 15억 7천만 달러 현금으로 인수했다고 밝혔다.
8. 찰스 리버 래보래토리즈 인터내셔널(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>)의 주식은 18.57% 하락했다. 이 회사는 <a href="https://www.benzinga.com//node/40222523" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">분기 실적</a>에서 글로벌 생명공학 고객들의 수요 추세가 약해지고 있다고 경고했습니다.
9. 모더나(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>)의 주식은 <a href="https://www.benzinga.com//node/40514864" target="_blank" rel="noreferrer noopener">17.81% 하락</a>했다.
10. 뉴로크린 바이오사이언시스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>)의 주식은 17.04% 락했습니다. 이는 <a href="https://www.benzinga.com//node/40632561" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">조현병 성인들</a>을 대상으로 한 NBI-1117568(NBI-&#8216;568)의 ​​2상 임상 연구에 대한 톱라인 데이터를 제시했다.
추가 읽기:
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%ec%96%b4%ed%8e%8c-%ec%87%bc%ed%94%bc%ed%8c%8c%ec%9d%b4-%ea%b7%b8%eb%a6%ac%ea%b3%a0-%ec%8a%a4%ed%83%80%eb%b2%85%ec%8a%a4%eb%8a%94-8%ec%9b%94-%ec%b5%9c%ea%b3%a0-%ec%84%b1%ea%b3%bc%eb%a5%bc-%eb%b3%b4/" target="_blank" rel="noopener">어펌, 쇼피파이 그리고 스타벅스는 8월 최고 성과를 보여준 10개 대형주 중 일부</a></li>
</ul>
Photo via Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

이들 10개 대형주는 지난주 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
1. 달러 제너럴(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DG#NYSE">DG</a>)의 주식은 회사가 2분기 실적과 매출이 예상보다 저조하게 나타났으며 <a href="https://www.benzinga.com//node/40623595" target="_blank" rel="noreferrer noopener">2024년 가이던스를 하향 조정</a>했다고 발표한 후 32.42% 하락했다. 많은 애널리스트들이 <a href="https://www.benzinga.com//node/40656935" target="_blank" rel="noreferrer noopener">주가 목표를 하향 조정</a>했다.
2. 슈퍼 마이크로 컴퓨터(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>)의 주식은 회사가 <a href="https://www.benzinga.com//node/40602417" target="_blank" rel="noreferrer noopener">10-K 제출을 지연할 것이라고 발표</a>한 후 20.21% 하락했다.
3. 옥타(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKTA#NASDAQ">OKTA</a>)의 주식은 <a href="https://www.benzinga.com//node/40613044" target="_blank" rel="noreferrer noopener">2분기 재무 실적</a> 발표 후 18.69% 하락했다. 여러 애널리스트들이 <a href="https://www.benzinga.com//node/40625762" target="_blank" rel="noreferrer noopener">회사의 주가 목표를 하향 조정</a>했다.
4. 퓨어 스토리지(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSTG#NYSE">PSTG</a>)의 주식은 회사가 <a href="https://www.benzinga.com//node/40613896" target="_blank" rel="noreferrer noopener">2분기 재무 실적</a>을 발표한 후 16.88% 하락했다. 애널리스트들이 주가 <a href="https://www.benzinga.com/quote/pstg/analyst-ratings" target="_blank" rel="noreferrer noopener">목표를 하향 조정</a>했다.
5. 뉴로크린 바이오사이언시스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>)의 주식은 15.66% 하락했다. 이 회사는 <a href="https://www.benzinga.com//node/40632561" target="_blank" rel="noreferrer noopener">조현병 성인</a>을 대상으로 한 NBI-1117568(NBI-&#8216;568)의 ​​2상 임상 연구에 대한 주요 데이터를 발표했다.
6. 심보틱(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYM#NASDAQ">SYM</a>)의 주식은 16.52% 하락했다. <a href="https://www.benzinga.com//node/40575289" target="_blank" rel="noreferrer noopener">짐 크레이머</a>는 &#8220;그 회사는 당신이 가고 싶은 회사가 아니다. 이번 하락 이후에도 너무 높다&#8221;고 말했다.
7. 달러 트리(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLTR#NASDAQ">DLTR</a>)의 주식은 달러 제너럴이 예상보다 저조한 <a href="https://www.benzinga.com//node/40625537" target="_blank" rel="noreferrer noopener">실적과 2024년 가이던스를 발표</a>한 후 12.18% 하락했다.
8. 테무의 모회사 PDD 홀딩(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDD#NASDAQ">PDD</a>)의 주식은 CEO가 하반기 도전 과제를 강조한 <a href="https://www.benzinga.com//node/40548945" target="_blank" rel="noreferrer noopener">2분기 재무 실적</a> 발표 후 12.80% 하락했다.
9. 코인베이스 글로벌(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>)의 주식은 7.71% 하락했다.
10. 마이크로스트레티지(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>)의 주식은 9.76% 하락했다.
추가 읽기:
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%ec%96%b4%ed%8e%8c-%eb%b0%8f-%eb%aa%bd%ea%b3%a0db%eb%8a%94-%ec%a7%80%eb%82%9c%ec%a3%bc-%ec%b5%9c%ea%b3%a0-%ec%84%b1%ea%b3%bc%eb%a5%bc-%eb%b3%b4%ec%97%ac%ec%a4%80-10%ea%b0%9c-%eb%8c%80%ed%98%95/" target="_blank" rel="noopener">어펌 및 몽고DB는 지난주 최고 성과를 보여준 10개 대형주 중 일부 (8월 25일-8월 31일)</a></li>
</ul>
사진 출처: Shutterstock

Comments

Neurocrine Biosciences

뉴스

에 대한 최신 뉴스 Neurocrine Biosciences (NASDAQ:NBIX) 주식

일요일, 9월 08, 2024

화요일, 9월 03, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌